- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
| Children | Adults | |
| Vd (ml/kg) | 110-127 | 75,8-138 |
| Cl (ml/hr/kg) | In children and adolescents approx. 35% higher compared to adults, resulting in lower systemic exposure | 3,5 |
| Renal elimination is less important route for clearance of rasburicase. | ||
| T1/2 (hr) | 15,7-22,5 | 15,7-22,5 |
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Prophylaxis and treatment of acute uricaemia |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
The risk of hypersensitivity and/or reduced effectiveness is greater in a second course of rasburicase.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Antidotes | ||
|---|---|---|
| V03AB15 | ||
| V03AB14 | ||
| Iron chelating agents | ||
|---|---|---|
| V03AC03 | ||
| V03AC02 | ||
| V03AC01 | ||
| Detoxifying agents for antineoplastic treatment | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| Drugs for treatment of hypoglycemia | ||
|---|---|---|
| V03AH01 | ||
| DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- Sanofi Winthrop Industrie, SmPC Fasturtec (EU/1/00/170/001-002) Rev 31;12-08-2024, www.ema.europa.eu
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
